BioCryst Pharma (BCRX) Reports In-Line Q3 EPS ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.14 +1.67%
EPS Growth %: -13.3%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -13.3%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $116.3 million versus the consensus estimate of $113.99 million.
GUIDANCE:
BioCryst Pharma sees FY2024 revenue of $443-448 million, versus the consensus of $436.3 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- A.O. Smith executive chairman to retire, CEO to assume chairman role
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
